Entrada Therapeutics, Inc. — Form 8-K
Filed October 14, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 52/100
What the filing says
Entrada announced positive Phase 1/2 topline data from Cohort 1 (n=8, 3:1 randomized to drug or placebo) of ELEVATE-45-201 studying ENTR-601-45 at 5 mg/kg in DMD exon 45-amenable patients. Primary objective met: favorable safety/tolerability with headache most common adverse event; no hypomagnesemia or renal safety concerns. Secondary objective met: 0.10% mean dystrophin increase vs. 0.02% decrease in placebo (p=0.03 nominal). Cohort 2 (10 mg/kg) enrollment complete; data expected H1 2027. Company plans dose escalation to 15 mg/kg in Cohort 3.
Why this rating
Early-stage clinical validation of lead candidate is material for clinical-stage biotech; 0.10% dystrophin increase modest but supports dose escalation. Company valued ~$191M; no revenue or partnership $ disclosed. Competitive but incremental progress vs. game-changing.
See more from October 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.